CAS 1402796-27-3

Fórmula: C31H34F7NO3

InChI: InChI=1S/C31H34F7NO3/c1-16(2)23-12-24(26(41-6)13-25(23)32)22-7-8-29(4,5)14-19(22)15-39-17(3)27(42-28(39)40)18-9-20(30(33,34)35)11-21(10-18)31(36,37)38/h9-13,16-17,27H,7-8,14-15H2,1-6H3/t17-,27-/m0/s1

Clave InChI: GBHPDJQHZADVAA-SOKVYYICSA-N

SMILES: C[C@H]1[C@H](OC(=O)N1CC2=C(CCC(C2)(C)C)C3=CC(=C(C=C3OC)F)C(C)C)C4=CC(=CC(=C4)C(F)(F)F)C(F)(F)F

CKD-519

CAS: 1402796-27-3

CKD-519

Fórmula: C₃₁H₃₄F₇NO₃

Pureza: 99.65%

Peso molecular: 601.6

Ref: 54-PC1032498

CKD-519

CAS: 1402796-27-3

Fórmula: C₃₁H₃₄F₇NO₃

Pureza: 99.65%

Peso molecular: 601.5954

Ref: IN-DA024BPE

Rocacetrapib

CAS: 1402796-27-3

Rocacetrapib is an investigational drug that belongs to the class of cholesteryl ester transfer protein (CETP) inhibitors. It has been shown to have antiviral activity against SARS-CoV and may be useful in the treatment of other viruses, such as HIV and influenza. Rocacetrapib has also been shown to inhibit cell growth and induce apoptosis in human lung cancer cells, which are resistant to cisplatin. This compound also binds to proteinase 3, suggesting a potential use in the treatment of Alzheimer's disease.

Fórmula: C₃₁H₃₄F₇NO₃

Pureza: Min. 95%

Peso molecular: 601.6 g/mol

Ref: 3D-CGC79627

CKD-519

CAS: 1402796-27-3

CKD-519: A CETP inhibitor with an IC50 of 2.3 nM, blocking cholesteryl ester transfer in serum.

Fórmula: C₃₁H₃₄F₇NO₃

Forma y color: Solid

Peso molecular: 601.6

Ref: TM-T14976